While anti-PD-L1 therapy alone had no effect on tumor growth, the anti-PD-L1 antibody with siTPT1-CNPs profoundly retarded tumor growth (Fig. 2h), and prolonged the survival (Fig. 2i). This evidence concerns the gene CD274 and neoplasm.